the recent
brought together three expert leaders in their field:
moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting.
In episode one, the physicians debated the follow-up analysis of a trial that questioned the necessity of early versus delayed ASCT, in light of newer therapies we have today.
In episode two, Dr. Prasad asked if selinexor, recently approved with support from the phase III BOSTON study, a good drug for the treatment of adults with multiple myeloma who have received at least one prior therapy?